has been cited by the following article(s):
[1]
|
Combining Bevacizumab with Knocked-Down β-Catenin Reduces
VEGF-A and Slug mRNA in HepG2 but not in Caco-2 Cell Lines
Current Molecular Medicine,
2022
DOI:10.2174/1573405617666210824120618
|
|
|
[2]
|
First-in-Human Phase I Study of MP0250, a First-in-Class DARPin Drug Candidate Targeting VEGF and HGF, in Patients With Advanced Solid Tumors
Journal of Clinical Oncology,
2021
DOI:10.1200/JCO.20.00596
|
|
|
[3]
|
A Tumor-in-Host DEB-Based Approach for Modeling Cachexia and Bevacizumab Resistance
Cancer Research,
2020
DOI:10.1158/0008-5472.CAN-19-0811
|
|
|
[4]
|
MP0250, a VEGF and HGF neutralizing DARPin® molecule shows high anti-tumor efficacy in mouse xenograft and patient-derived tumor models
Oncotarget,
2017
DOI:10.18632/oncotarget.21738
|
|
|